Philippe Parone, Phd

CSO 

Dr Parone is an innovative scientist and accomplished leader in the biotech industry, with over 25 years of experience spanning both academia and the private sector. Before joining EsoBiotec, Philippe served as Director of Industrialization at Celyad Oncology in Belgium, with a pivotal role in directing research programs and advancing both autologous and allogeneic cell therapies into first in human studies.

Prior to that, he was Associate Director at Fate Therapeutics in San Diego, where he led the development of iPSC and patient derived immuno-regulatory cell therapies for the treatment of immune disorders, including T1D, MS and GvHD and oversaw companywide IND enabling safety pharmacology studies for iPSC derived cell therapy products for the treatment of hematological malignancies.

Philippe began his career as a postdoctoral fellow at the University of Geneva, later transitioning to the Ludwig Institute for Cancer Research at the University of California San Diego, making key contributions in the field of neurodegeneration and motor neuron disease. He holds a PhD in Biochemistry from the University of Cambridge, UK.